Holen Sie sich die Stockscreener-App
209.48
1.91%
3.93
Vorhandelsmarkt:
212.86
3.38
+1.61%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$205.55
Offen:
$208.1
24-Stunden-Volumen:
2.29M
Relative Volume:
0.38
Marktkapitalisierung:
$324.75B
Einnahmen:
$58.80B
Nettoeinkommen (Verlust:
$10.24B
KGV:
63.89
EPS:
3.2788
Netto-Cashflow:
$8.98B
1W Leistung:
+8.31%
1M Leistung:
+121.93%
6M Leistung:
+164.60%
1J Leistung:
+184.70%
1-Tages-Spanne:
$207.85
$211.27
1-Wochen-Bereich:
$199.19
$211.27
52-Wochen-Spanne:
$61.24
$211.27
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
209.48 | 318.66B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
1,036.05 | 981.09B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.33 | 586.69B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
232.86 | 409.15B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
166.17 | 311.22B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider - GlobeNewswire Inc.
Stock Watch: AstraZeneca’s Fourth-Quarter Results Are Solid, But Not Vintage - Citeline News & Insights
HighTower Advisors LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
Risk Off: Can Safe Bulkers Inc lead its sector in growthPortfolio Performance Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Crestwood Advisors Group LLC Has $40.30 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
Denali Advisors LLC Has $689,000 Stock Position in AstraZeneca PLC $AZN - MarketBeat
Below £151, here’s why AstraZeneca’s share price looks a steal to me under £228.62 after strong 2025 results - The Motley Fool UK
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's Why - MarketBeat
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Strong Multi‑Year Share Gains? - Yahoo Finance UK
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor - Proactive Investors
Oddo BHF raises TP for AstraZeneca shares - marketscreener.com
AstraZeneca awards $3.4 million to US nonprofits to expand healthcare access - MSN
AstraZeneca PLC $AZN Shares Sold by ING Groep NV - MarketBeat
AstraZeneca PLC $AZN Shares Acquired by Cibc World Market Inc. - MarketBeat
AstraZeneca PLC (AZN) Stock Price, Trades & News - GuruFocus
Krilogy Financial LLC Takes $731,000 Position in AstraZeneca PLC $AZN - MarketBeat
Cookson Peirce & Co. Inc. Invests $1.05 Million in AstraZeneca PLC $AZN - MarketBeat
Advisors Asset Management Inc. Acquires 8,453 Shares of AstraZeneca PLC $AZN - MarketBeat
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory - Yahoo Finance
Shore Capital lowers AstraZeneca to 'hold' - Sharecast.com
Published on: 2026-02-13 16:14:39 - mfd.ru
AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results i - GuruFocus
AstraZeneca's BREZTRI Shows Significant Asthma Improvement in Phase III Trials - Intellectia AI
Caprock Group LLC Takes $3.10 Million Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Announces BrePREMIUM Trial Results - Intellectia AI
AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials - marketscreener.com
AstraZeneca Earnings: Strong Finish to Year, and Busy Schedule of Data Readouts Ahead - Morningstar Canada
AstraZeneca - Britannica
AstraZeneca PLC (LON:AZN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
What makes AstraZeneca (AZN) a strong growing company? - MSN
Market voices: Paramount-WBD bid, Holtec IPO, AstraZeneca - MSN
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
6,649 Shares in AstraZeneca PLC $AZN Acquired by Westover Capital Advisors LLC - MarketBeat
Here’s What Lifted AstraZeneca PLC (AZN) in Q4 - Insider Monkey
Madison Asset Management LLC Trims Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca - Benzinga
Kangtai Drops Plan for China Vaccine JV With AstraZeneca - Citeline News & Insights
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
Former AstraZeneca regional head officially charged in China - MSN
China charges former AstraZeneca regional head Leon Wang - marketscreener.com
AstraZeneca (AZN) Faces Legal Challenges in China - GuruFocus
Former AstraZeneca regional head charged in China (AZN:NYSE) - Seeking Alpha
AstraZeneca And Daiichi Sankyo Stack The Odds For Datroway’s Lung Cancer Bets - Citeline News & Insights
How AstraZeneca shot for the moon — and hit - Financial Times
China charges former AstraZeneca executive Leon Wang - marketscreener.com
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
AstraZeneca's ex-chief in China formally charged with insurance fraud - The Edge Malaysia
Chinese Authorities Charge AstraZeneca's Ex-China Business Head - marketscreener.com
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline - Yahoo Finance UK
AstraZeneca PLC (NYSE:AZN) Q4 2025 Earnings Call Transcript - Insider Monkey
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US - marketscreener.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.88%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):